Literature DB >> 23588340

Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.

Bethany Mikles1, Jennifer Levine, Tatyana Gindin, Govind Bhagat, Prakash Satwani.   

Abstract

The treatment of anaplastic large cell lymphoma (ALCL) has largely relied on anthracycline-based chemotherapy. Targeted lymphoma therapy, using an anti-CD30 antibody, provides an innovative treatment modality for specific lymphomas, particularly ALCL. Brentuximab vedotin (BV; SGN-35) uses a CD30 monoclonal antibody to generate apoptosis of targeted lymphoma cells. We present a pediatric patient with ALCL who experienced second relapse after standard chemotherapy and autologous and allogeneic hematopoietic stem cell transplantation. This patient has been treated with BV as a single agent and has sustained remission for several months. BV offers a targeted treatment for relapsed ALCL, even after multiple relapses.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 23588340     DOI： 10.1097/MPH.0b013e31828aff2c

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


  4 in total

1.  Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC.

Authors:  M Strullu; C Thomas; M-C Le Deley; A Chevance; J Kanold; Y Bertrand; C Jubert; J-H Dalle; C Paillard; A Baruchel; L Lamant; G Michel; L Brugières
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

2.  Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.

Authors:  Lin Yu; Ying Lu; Yuqin Yao; Yu Liu; Yuxi Wang; Qinhuai Lai; Ruirui Zhang; Wenting Li; Ruixue Wang; Yuyin Fu; Yiran Tao; Shuli Yi; Lantu Gou; Ligong Chen; Jinliang Yang
Journal:  Oncotarget       Date:  2017-12-26

Review 3.  Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future.

Authors:  Caryn E Sorge; Jenny K McDaniel; Ana C Xavier
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-19

Review 4.  Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.

Authors:  Ioannis Kyriakidis; Eleni Vasileiou; Claudia Rossig; Emmanuel Roilides; Andreas H Groll; Athanasios Tragiannidis
Journal:  J Fungi (Basel)       Date:  2021-03-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.